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Abstract 
Solitary fibrous tumor (SFT) is a rare mes-
enchymal neoplasm which may be found every-
where in the body. It is now distinguished into
two  forms,  pleural  and  extrapleural,  which
morphologically resemble each other. Abdomi  -
nal localizations are quite rare, with 10 cases
only  reported  in  bladder;  rarely  they  can  be
source  of  paraneoplastic  syndromes  (i.e.,
hypoglycemia secondary to insulin-like growth
factor). In April 2006 a 74-year-old white male
presented with chills, diaphoresis and acute
abdominal pain with hematuria. At admission
in emergency he underwent an abdominal X-
ray  (no  pathological  findings)  and  an  ultra-
sound examination of the kidneys and urinary
tract, which revealed a pelvic hyperechogenic
neoformation  measuring  approximately
10ﾥ8ﾥ7  cm,  compressing  the  bladder.  Blood
chemistry at admission revealed only a mild
neutrophilic leucocytosis (WBC 16600, N 80%,
L  11%),  elevated  fibrinogen  and  ESR,  and
hypoglycemia (38 mg/dL). Macro  scopic hema-
turia was evident, while urinocolture was neg-
ative.  Contrast  enhanced  CT  scan  of  the
abdomen  and  pelvic  region  revealed  a  large
round  neoformation  dislocating  the  bladder,
with an evident contrast-enhanced periphery
and a central necrotic area. Continuous infu-
sion of glucose 5% solution was necessary in
order to maintain blood glucose levels above 50
mg/dL. The patient underwent complete surgi-
cal resection of an ovoidal mass coated by adi-
pose tissue, with well delimited margins; his-
tological findings were consistent with solitary
fibrous  tumor (SFT).  Hypoglycemia  resolved
completely with removal of the growth. In this
case report we describe a SFT growing in the
bladder, a quite rare localization, which pre-
sented a unique hypoglycemia. In contrast to
the majority of cases reported in the literature,
the behavior of this SFT was not aggressive,
and,  since  the  patient  is  still  alive,  surgical
resection was considered conclusive.
Introduction
Solitary fibrous tumor (SFT) is a rare mes-
enchymal neoplasm: it was first described in
1931  by  Klemperer  and  Rabin  as  a  distinct
mesothelial  tumor  arising  from  the  pleura.1
Despite this first description, SFTs have been
reported in numerous other extraserosal sites,
thus  supporting  the  tumor’s  mesenchymal
rather than mesothelial origin.2 For this rea-
son, it is now distinguished into two entities,
pleural and extrapleural, which morphological-
ly resembling each. 
Extrapleural  SFTs  are  observed  in  middle
aged adults (between 20 and 70 years, median
50  years),  and  affect  both  sexes  equally.
Occasional  cases  can  occur  in  adolescents.
They can be found in any location: to the best
of our knowledge, nearly 40% are found in sub-
cutaneous tissues, while others are found in
deep  soft  tissues  of  the  extremities,  in  the
head  and  neck  region  (including    larynx,
hypopharynx,  parapharyngeal  space,  tongue,
orbit,  paranasal  sinuses  and  nasal  cavity),
meninges, orbit, thoracic wall, mediastinum,
pericardium,  peritoneum,  pelvis,  adrenal
glands, liver and urogenital system.
Abdominal  localizations  are  quite  rare:  of
the 160 cases appearing in the literature, 28
have  been  reported  in  the  liver,  25  in  the
prostate, 20 in the kidneys, 12 in the retroperi-
toneum, and only 10 in bladder; other localiza-
tions are anecdotal.
Clinically,  it  is  a  slow-growing,  painless,
well-delineated exophytic mass; large tumors
can be due to compression symptoms, while
rarely  they  are  the  source  of  paraneoplastic
syndromes  (i.e.,  hypoglycemia  secondary  to
insulin-like growth factor). The dimensions of
a SFT can vary from 1 to 25 cm in diameter.
Case Report
In April 2006 a 74-year-old white male pre-
sented  with  chills,  diaphoresis  and  acute
abdominal pain with hematuria. He was not
diabetic, was a smoker (about 30 cigarettes/
day) and in 2005 had undergone a complete
surgical resection of a vesical leiomyoma. On
admission  to  our  emergency  department  he
underwent an abdominal X-ray (which showed
no  pathological  findings)  and  an  ultrasound
examination of the kidneys and urinary tract,
which revealed a pelvic hyperechogenic neo-
formation that measured approximately 10ﾥ8
ﾥ7  cm  and  that  compressed  bladder.  Blood
chemistry at admission revealed only a mild
neutrophilic leukocytosis (WBC 16600, N 80%,
L  11%),  elevated  fibrinogen  and  ESR,  and
hypoglycemia (38 mg/dL). Macroscopic hema-
turia was evident, while urinocolture was neg-
ative.  Contrast  enhanced  CT  scan  of  the
abdomen  and  pelvic  region  revealed  a  large
round  neoformation  dislocating  the  bladder,
with an evident contrast-enhanced periphery
and  a  central  necrotic  area  (Figure  1).
Continuous  infusion  of  glucose  5%  solution
was necessary in order to maintain blood glu-
cose levels above 50 mg/dL. The patient under-
went complete surgical resection of an ovoidal
mass coated by adipose tissue and with well
delimited  margins  (Figure  2).  Histological
findings were consistent with SFT. The patient
underwent  radical  excision  of  the  neoplasm
and has since not been treated with any fur-
ther  therapies.  He  is  still  alive  without  any
clinical-radiological  evidence  of  recurrence.
Hypoglycemia  resolved  completely  with
removal of the neoplasm.
Discussion
The  histological  appearance  of  SFT  may
resemble and overlap with other benign and
malignant diagnostic entities, such as heman-
giopericytoma,  leiomyoma,  nodular  fasciitis,
inflammatory  myofibroblastic  tumor,  fibro-
matosis,  and  benign  peripheral  nerve  sheet
tumor.
3 It must be noted that tumors with sim-
ilar features have been described in literature
with different names, thereby creating some
confusion among pathologists and clinicians.
The unifying morphological criterion of all
these lesions is represented by a well-circum-
scribed,  tan-colored,  rubbery  mass,  which  is
often tethered by a pedicle and partially encap-
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sulated.  Microscopically  it  is  described  as  a
patternless proliferation  of  bland-looking
spindly to oval epithelioid cells that form short
fascicles and/or clusters, admixed with thick or
thin collagen bands, and a prominent branch-
ing vasculature. Mature adipocytes and giant
multinucleated stromal cells may be present.
3,4
Mitoses are generally scarce, rarely exceeding
3 mitoses per 10 hp fields.
Malignant  counterparts  are  usually  hyper-
cellular  lesions,  showing  variable  cytologic
(focally  moderate  to  marked)  atypia,  tumor
necrosis, infiltrative margins and higher fre-
quency  of  mitoses.
5 Immunohistochemical
staining for vimentin, Bcl2, CD 99 and CD34
immunoreactivity isperformed in order to dis-
criminate SFT from other neoplasms; it is usu-
ally  completely  negative  for  S-100  protein,
cytocheratin AE1/AE3 and neurofilaments. In
some  cases  immunohistochemical  negativity
has  been  reported  for  c-kit,  CAM  5.2,  factor
XIIIa, HMB-45, AE-1, SMA, CD31, and Fli-1.
6,7
One  classification  distinguishes  SFT  into
two subcategories: fibroblastic and myofibrob-
lastic. The latter strongly express alfa smooth-
muscle actin and desmin, while the former do
not.
8 Solitary fibrous tumors are karyotipically
variable, and currently available data do not
evince any anomalies that are common to or
characteristic  of    these  lesions.  Cytogenetic
data  are  very  limited  and  suggest  predomi-
nantly structural abnormalities and numerical
imbalances.
9
The tumour is difficult to detect because it
has no typical radiologic features: on X-ray it
appears as a moderately radio-opaque mass;
on ultrasonography as a nodule with generally
well-defined  borders  and  a  homogeneous
echostructure. In addition to these means, sec-
ond-level  imaging  techniques,  such  as  con-
trast-enhanced CT scan and MRI, are usually
performed: the former reveals a well-defined
capsule  surrounding  a  nearly  homogeneous
mass with progressive enhancement from the
arterial to the venous phase and occasionally
multiple small non-enhancing portions.
10
Despite  their  unpredictable  behavior,  10-
15% of SFTs are aggressive. Local recurrence
or onset of metastasis depends mainly on the
following  prognostic  parameters:  histological
features (nuclear atypia, increased cellularity,
necrosis,  and  more  than  4  mitoses  per  10
HPF), localization (approximately 10 to 15% of
SFTs  located  outside  the  thoracic  cavity  are
recurrent or metastatic), dimensions (>10 cm)
and resectability (the most important). 
Although most SFTs are characterized by a
non-aggressive  clinical  course,  malignant
transformation  and  a  large  size  have  been
associated with a poor outcome, thus making
long-term follow-up in all cases strongly advis-
able.  Lesions  located  in  the  mediastinum,
abdomen,  pelvis  or  retroperitoneum  tend  to
behave  more  aggressively  than  those  in  the
limbs. Metastases are most often reported in
the lungs, bone and liver.
Non  islet-cell  hypoglycemia  (Doege  Potter
syndrome)  due  to  the  production  of  high
molecular weight insulin-like growth factors
11
is the most frequent associated paraneoplastic
syndrome: it is described in only 40 of all cases
of SFT reported in the literature,
11 but in near-
ly 70% of these it has a malignant behavior or
a poor survival from diagnosis (30% have a
benign behavior or no reported deaths during
follow-up). Bladder localizations with associat-
ed hypoglycemia are very rare.
Because of the unpredictable behavior that
SFTs display and the lack of consistent data in
literature, surgery is considered the treatment
of  choice  whenever  possible.  The  use  of
chemotherapy  is  reserved  to  metastatic  or
symptomatic  non-resectable  SFTs,  but  there
are no standard chemotherapeutic indications
or regimens. Even though SFTs are considered
relatively  chemoresistant,  the  most  effective
drugs  seem  to  be  anthracyclines  and  ifos-
famide,  followed  by  gemcitabine  and  dacar-
bazine, which are commonly used in soft tis-
sue sarcomas.
12,13
Radiation therapy is of some benefit, when
applicable,  also  in  combination  with
chemotherapy.14 The novel targeted drug ima-
tinib mesilate seems to exert some activity on
SFT expressing the wild type platelet-derived
growth factor receptor-b: its in vitro15 and in
vivo16 inhibitory  activity  in  chemo-  and
radioresistant  malignant  SFT  has  recently
been reported.
Conclusions
In this case report we describe a SFT grow-
ing in the bladder, a quite infrequent localiza-
tion,  which  presented  a  unique  associated
hypoglycemia.
In contrast with the majority of cases report-
ed in the literature, the behavior of this SFT
was  not  aggressive.  Surgical  resection  was
considered conclusive, given that the patient is
still alive, despite the initial presentation with
paraneoplastic syndrome.
In view of the recent introduction of targeted
therapies” in cancer treatment and the rarity of
this  neoplasm,  further  efforts  are  needed  in
order to collect a critical mass of biopsy speci-
mens and to perform more exhaustive anato-
mopathological and molecular examinations.
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